The current valuation score of ACADIA Pharmaceuticals Inc is 6.50, ranking 312 out of 390 in the Biotechnology & Medical Research industry. Its current P/E ratio is 13.02, which is 693.64% below the recent high of 103.35 and 16701.56% above the recent low of -2161.97.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.